Fuzzy-Based PROMETHEE Method for Performance Ranking of SARS-CoV-2 IgM Antibody Tests.
COVID-19
IgM
MCDM
PROMETHEE
SARS-CoV-2
fuzzy logic
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
17 Nov 2022
17 Nov 2022
Historique:
received:
13
10
2022
revised:
07
11
2022
accepted:
14
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Antibody tests, widely used as a complementary approach to reverse transcriptase-polymerase chain reaction testing in identifying COVID-19 cases, are used to measure antibodies developed for COVID-19. This study aimed to evaluate the different parameters of the FDA-authorized SARS-CoV-2 IgM antibody tests and to rank them according to their performance levels. In the study, we involved 27 antibody tests, and the analyzes were performed using the fuzzy preference ranking organization method for the enrichment evaluation model, a multi-criteria decision-making model. While criteria such as analytical sensitivity, specificity, positive predictive value, and negative predictive value were evaluated in the study, the ranking was reported by determining the importance levels of the criteria. According to our evaluation, Innovita 2019-nCoV Ab Test (colloidal gold) was at the top of the ranking. While Cellex qSARS-CoV-2 IgG/IgM Rapid Test and Assure COVID-19 IgG/IgM Rapid Tester ranked second and third on the list, the InBios-SCoV 2 Detect Ig M ELISA Rapid Test Kit was determined as the least preferable. The fuzzy preference ranking organization method for enrichment evaluation, which has been applied to many fields, can help decision-makers choose the appropriate antibody test for managing COVID-19 in controlling the global pandemic.
Identifiants
pubmed: 36428889
pii: diagnostics12112830
doi: 10.3390/diagnostics12112830
pmc: PMC9689080
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Lab Anal. 2022 Jul;36(7):e24374
pubmed: 35446996
J Clin Virol. 2021 Jan;134:104690
pubmed: 33253926
Lancet. 2022 Feb 19;399(10326):757-768
pubmed: 34942102
J Microbiol Immunol Infect. 2021 Oct;54(5):983-986
pubmed: 33836943
Can J Infect Dis Med Microbiol. 2022 Oct 15;2022:4677720
pubmed: 36284529
Comput Math Methods Med. 2020 Aug 6;2020:1560250
pubmed: 32802146
Pract Lab Med. 2021 Mar;24:e00201
pubmed: 33501369
J Healthc Eng. 2021 Jan 22;2021:8864522
pubmed: 33552457
Sci Rep. 2020 Oct 6;10(1):16561
pubmed: 33024213
Int J Infect Dis. 2021 Feb;103:636-641
pubmed: 33227517
Am J Clin Pathol. 2020 Aug 5;154(3):293-304
pubmed: 32583852
Bioanalysis. 2022 Mar;14(6):325-340
pubmed: 35234530
Micromachines (Basel). 2021 Nov 27;12(12):
pubmed: 34945314
J Adv Res. 2021 Aug 21;37:147-168
pubmed: 35475277
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Exp Ther Med. 2020 Nov;20(5):13
pubmed: 32934678
Arch Pathol Lab Med. 2021 Feb 1;145(2):145-167
pubmed: 32886738
Biosens Bioelectron. 2021 Jun 1;181:113160
pubmed: 33740542
EJIFCC. 2021 Oct 18;32(3):311-327
pubmed: 34819821
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Cell Biosci. 2021 Jul 19;11(1):136
pubmed: 34281608
iScience. 2020 Aug 21;23(8):101406
pubmed: 32771976
Diagnostics (Basel). 2020 Jul 04;10(7):
pubmed: 32635444
J Mol Histol. 2020 Dec;51(6):613-628
pubmed: 33011887